All In Biotech

Drug Trial Radar · NCT04077099

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

95

Actual

Start

Jan 7, 2020

Primary completion

Jul 6, 2027

Study completion Jul 6, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Sep 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body

Conditions

  • NSCLC

Interventions

  • REGN5093Drug

    Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days
  2. Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 12 years
  3. Incidence and severity of adverse events of special interest (AESIs)Time frame: Through study completion, an average of 12 years
  4. Incidence and severity of serious adverse events (SAEs)Time frame: Through study completion, an average of 12 years
  5. Incidence and severity of grade ≥3 laboratory abnormalitiesTime frame: Through study completion, an average of 12 years
  6. REGN5093 concentrations in serum over timeTime frame: Through study completion, an average of 12 years
  7. Objective response rate (ORR) per RECIST 1.1Time frame: Through study completion, an average of 12 years

Locations

29 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California Irvine Medical Center - Bldg 56, RT81, Rm 241

    Orange, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Moffitt Cancer Center - McKinley Drive

    Tampa, Florida

  • Dana Farber Harvard Cancer Center Consortium

    Boston, Massachusetts

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Pittsburgh UPMC - Clinical Research Services

    Pittsburgh, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Centre Hospitalier Universitaire de Grenoble

    Grenoble, France

  • Centre Hospitalier Regional Universitaire (CHRU) Montpellier Arnaud de Villeneuve

    Montpellier, France

  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou

    Rennes, Bretange, France

  • Institut Bergonie

    Bordeaux, New Aquitaine, France

  • Centre Francois Baclesse (CFB)

    Caen, Normandy, France

  • Pusan National University Hospital

    Busan, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seol St. Mary's Hospital

    Seoul, South Korea

  • Boramae Medical Center

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • National Cancer Center

    Gyeonggi-do, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • The Catholic University Of Korea St. Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea

  • Haeundae Paik Hospital

    Pusan, Gyeongsangnam-do, South Korea

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea

  • Gachon University Gil Medical Center

    Incheon, Namdong-gu, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.